Gypenoside XVII (Synonyms: 七叶胆苷XVII; Gynosaponin S)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Gypenoside XVII  (Synonyms: 七叶胆苷XVII; Gynosaponin S) 纯度: 99.63%

Gypenoside XVII 是一种属于绞股蓝皂甙类的新型植物雌激素,可激活雌激素受体 (estrogen receptors)。

Gypenoside XVII                                          (Synonyms: 七叶胆苷XVII; Gynosaponin S)

Gypenoside XVII Chemical Structure

CAS No. : 80321-69-3

规格 价格 是否有货 数量
1 mg ¥400 In-stock
5 mg ¥1000 In-stock
10 mg ¥1600 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Gypenoside XVII 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Glycoside Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Active Compound Library
  • Food-Sourced Compound Library
  • Plant-Sourced Natural Product Library
  • Human Metabolite Library
  • Nuclear Receptor Compound Library
  • Membrane Protein-targeted Compound Library
  • Membrane Receptor-targeted Compound Library

同靶点产品:

同靶点蛋白产品:

生物活性

Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.

IC50 & Target

Estrogen receptor[1]

体外研究
(In Vitro)

The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs. Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis. Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability. The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII [1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Gypenoside XVII 相关抗体:

体内研究
(In Vivo)

Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/- model group[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

947.15

Formula

C48H82O18

CAS 号

80321-69-3

性状

固体

颜色

White to off-white

中文名称

七叶胆苷 XVII;绞股蓝皂苷 XVII

结构分类
  • Terpenoids
  • Triterpenes
初始来源
  • 植物
  • 葫芦科
  • 绞股蓝
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO 中的溶解度 : ≥ 100 mg/mL (105.58 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 41.67 mg/mL (44.00 mM; 超声助溶)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0558 mL 5.2790 mL 10.5580 mL
5 mM 0.2112 mL 1.0558 mL 2.1116 mL
10 mM 0.1056 mL 0.5279 mL 1.0558 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

=

浓度

×

体积

×

分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×

体积 (start)

V1

=

浓度 (final)

C2

×

体积 (final)

V2

In Vivo:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.64 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。

  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.64 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

  • 方案 三

    请依序添加每种溶剂: 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (2.64 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

以下溶解方案,请直接配置工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: PBS

    Solubility: 25 mg/mL (26.39 mM); 澄清溶液; 超声助溶

扫码获得
动物溶解方案

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量

计算结果
工作液所需浓度 : mg/mL

该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
免费服务热线:021-50837765
E-mail:sales@jinpanbio.com
技术支持电话:021-50837765
技术支持邮箱:sales@jinpanbio.com

纯度 & 产品资料

纯度: 99.63%

Data Sheet (631 KB) SDS (252 KB)

COA (272 KB) HNMR (450 KB) RP-HPLC (174 KB) MS (279 KB)

产品使用指南 (1538 KB)

参考文献
  • [1]. Yang K, et al. Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ERα-Mediated PI3K/Akt Pathway. Int J Mol Sci. 2017 Feb 9;18(2). pii: E77.  [Content Brief]

Cell Assay
[1]

For the establishment of an Ox-LDL-induced apoptosis model and measurement of Gypenoside XVII’s protective effect, the HUVECs are seeded in 96-well plates at a density of 105 cells per mL and grown for 24 h. Then, the HUVECs are pretreated with Gypenoside XVII (6.25, 12, 25, 50, 100 μg/mL) for 12 h in serum-free endothelial cell basal medium, followed by incubation with Ox-LDL (100 μg/mL, 24 h) which does not have Gypenoside XVII. After 24 h, the treated HUVECs are incubated with 5 mg/mL MTT in fresh medium for an additional 4 h. Absorbance is measured at 570 nm using a plate reader[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
A total of 42 ApoE-/- mice and 12 male C57BL/6J mice with the same age and body weight (approximately 20 g in body weight and 6 weeks old) are randomly divided into 4 groups (12 mice for each group) and orally administered the following once a: C57 control group (vehicle; 0.5% sodium carboxymethylcellulose, CMC-Na); ApoE-/- model group (vehicle; 0.5% CMC-Na); ApoE-/-+Gypenoside XVII group (Gypenoside XVII, 50 mg/kg via i.g. ); ApoE-/-+probucol group (Probucol, 2 mg/kg via i.g.). Probucol is an antioxidant drug used as a positive control. After two weeks of acclimatization, all the mice are fed a high-fat diet including 0.3% cholesterol and 20% pork fat for 10 weeks. They are maintained in pathogen-free conditions at approximately 22±1°C on a 12 h light-dark cycle with free access to food and water. The body weights are determined every two weeks. After 10 weeks of the treatments, all animals are anesthetized with pentobarbital sodium and killed after being deprived of food overnight. Serum is immediately separated from blood samples by centrifugation at 3600 rpm for 15 min, and the tissue samples (heart and aorta) are rapidly removed and frozen in -8°C.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Yang K, et al. Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ERα-Mediated PI3K/Akt Pathway. Int J Mol Sci. 2017 Feb 9;18(2). pii: E77.  [Content Brief]

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务